Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3689-3696

  Denisova, Oxana V ^a   Sod̈erholm, Sandra ^a,b   Virtanen, Salla ^c   Von Schantz, Carina ^a   Bychkov, Dmitrii ^a   Vashchinkina, Elena ^c   Desloovere, Jens ^a   Tynell, Janne ^a   Ikonen, Niina ^a   Theisen, Linda L ^d   Nyman, Tuula A ^b   Matikainen, Sampsa ^a   Kallioniemi, Olli ^a   Julkunen, Ilkka ^a   Muller, Claude P ^d   Saelens, Xavier ^e   Verkhusha, Vladislav V ^f   Kainov, Denis E ^a,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e GHENT UNIVERSITY   (Belgium)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g IAULIAI UNIVERSITY   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; OBATOCLAX; CYTOKINE; FUSED HETEROCYCLIC RINGS; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEINASE INHIBITOR; SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA; INFLUENZA PH1N1 VIRUS INFECTION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N9; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HOST PATHOGEN INTERACTION; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; METABOLISM; MOLECULAR GENETICS; VIRAL PLAQUE ASSAY; VIROLOGY;

CELL LINE; CYTOKINES; HETEROCYCLIC COMPOUNDS, 3-RING; HOST-PATHOGEN INTERACTIONS; HUMANS; IN VITRO TECHNIQUES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEIN V-AKT; PHOSPHOPROTEINS; PROTEASE INHIBITORS; RNA, SMALL INTERFERING; TRANSFECTION; VIRAL PLAQUE ASSAY;

EID: 84903140700     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02798-13     Document Type: Article

References (38)

1. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, Raghwani J, Bhatt S, Peiris JS, Guan Y, Rambaut A. 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459:1122-1125. http://dx.doi.org/10.1038/nature08182.
2. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. 2009. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83:10366-10373. http://dx.doi.org/10.1128/JVI.01200-09.
3. Samson M, Pizzorno A, Abed Y, Boivin G. 2013. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 98:174-185. http://dx.doi.org/10. 1016/j.antiviral.2013.03.014.
4. Hayden FG. 2013. Newer influenza antivirals, biotherapeutics and combinations. Influenza and other respiratory viruses. 7(Suppl 1):63-75. http://dx.doi.org/10.1111/irv.12045.
5. Muller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, Kainov DE. 2012. Emerging cellular targets for influenza antiviral agents. Trends Pharmacol. Sci. 33:89-99. http://dx.doi.org/10.1016/j.tips.2011.10.004.
6. Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X, Kainov DE. 2012. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J. Biol. Chem. 287:35324-35332. http://dx.doi.org/10.1074/jbc.M112.392142.
7. Theisen LL, Muller CP. 2012. EPs 7630 (Umckaloabo), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral Res. 94:147-156. http://dx.doi.org/10.1016/j.antiviral.2012.03. 006.
8. Muller KH, Kainov DE, El Bakkouri K, Saelens X, De Brabander JK, Kittel C, Samm E, Muller CP. 2011. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. Br. J. Pharmacol. 164:344-357. http://dx.doi.org/10.1111/j.1476-5381.2011.01346.x.
9. Planz O. 2013. Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Res. 98:457-468. http://dx.doi.org/10.1016/j.antiviral.2013.04.008.
10. Ludwig S. 2009. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 64:1-4. http://dx.doi.org/10.1093/jac/dkp161.
11. Ehrhardt C, Marjuki H, Wolff T, Nurnberg B, Planz O, Pleschka S, Ludwig S. 2006. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell. Microbiol. 8:1336-1348. http://dx.doi.org/10.1111/j.1462-5822.2006.00713.x.
12. Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y. 2007. Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation. J. Gen. Virol. 88:942-950. http://dx.doi.org/10.1099/vir.0.82483-0. (Pubitemid 46359565)
13. Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF. 2012. Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antiviral Chem. Chemother. 22:205-215. http://dx.doi.org/10.3851/IMP2080.
14. Zhirnov OP, Klenk HD. 2007. Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis 12:1419-1432. http://dx.doi.org/10.1007/s10495-007-0071-y. (Pubitemid 46988278)
15. Lebreton S, Jaunbergs J, Roth MG, Ferguson DA, De Brabander JK. 2008. Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide. Bioorg. Med. Chem. Lett. 18:5879-5883. http://dx.doi.org/10.1016/j.bmcl.2008.07. 003.
16. Lakspere T, Tynell J, Kaloinen M, Vanlede M, Parsons A, Ikonen N, Kallio-Kokko H, Kantele A, Mattila P, Almusa H, Julkunen I, Kainov D, Kakkola L. 2014. Full-genome sequences of influenza A(H1N1)pdm09 viruses isolated from Finnish patients from 2009 to 2013. Genome Announc. 2(1):e01004-13. http://dx.doi.org/10.1128/genomeA.01004-13.
17. Schotsaert M, Ysenbaert T, Neyt K, Ibanez LI, Bogaert P, Schepens B, Lambrecht BN, Fiers W, Saelens X. 2013. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol. 6:276-287. http://dx.doi.org/10.1038/mi.2012.69.
18. Ducatez MF, Olinger CM, Owoade AA, De Landtsheer S, Ammerlaan W, Niesters HG, Osterhaus AD, Fouchier RA, Muller CP. 2006. Avian flu: multiple introductions of H5N1 in Nigeria. Nature 442:37. http://dx.doi.org/10.1038/ 442037a. (Pubitemid 44064202)
19. Ohman T, Lietzen N, Valimaki E, Melchjorsen J, Matikainen S, Nyman TA. 2010. Cytosolic RNA recognition pathway activates 14-3-3 protein mediated signaling and caspase-dependent disruption of cytokeratin network in human keratinocytes. J. Proteome Res. 9:1549-1564. http://dx.doi.org/10.1021/ pr901040u.
20. Bimbo LM, Denisova OV, Makila E, Kaasalainen M, De Brabander JK, Hirvonen J, Salonen J, Kakkola L, Kainov D, Santos HA. 2013. Inhibition of influenza a virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles. ACS Nano 7:6884-6893. http://dx.doi.org/10.1021/nn402062f.
21. Kakkola L, Denisova OV, Tynell J, Viiliainen J, Ysenbaert T, Matos RC, Nagaraj A, Ohman T, Kuivanen S, Paavilainen H, Feng L, Yadav B, Julkunen I, Vapalahti O, Hukkanen V, Stenman J, Aittokallio T, Verschuren EW, Ojala PM, Nyman T, Saelens X, Dzeyk K, Kainov DE. 2013. Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. Cell Death Dis. 4:e742. http://dx.doi.org/10.1038/cddis.2013.267.
22. Wang J, Nikrad MP, Phang T, Gao B, Alford T, Ito Y, Edeen K, Travanty EA, Kosmider B, Hartshorn K, Mason RJ. 2011. Innate immune response to influenza A virus in differentiated human alveolar type II cells. Am. J. Respir. Cell Mol. Biol. 45:582-591. http://dx.doi.org/10.1165/rcmb.2010-0108OC.
23. Socodato R, Brito R, Portugal CC, de Oliveira NA, Calaza KC, Paes-de-Carvalho R. 14 February 2014. The nitric oxide-cGKII system relays death and survival signals during embryonic retinal development via AKT-induced CREB1 activation. Cell Death Differ. http://dx.doi.org/10.1038/cdd.2014.11.
24. Dent P. 2014. Crosstalk between ERK, AKT, and cell survival. Cancer Biol. Ther. 15:245-246. http://dx.doi.org/10.4161/cbt.27541.
25. Saraswati S, Kumar S, Alhaider AA. 2013. Alpha-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol. Cancer 12:147. http://dx.doi.org/10.1186/1476-4598-12-147.
26. Zhang J, Shemezis JR, McQuinn ER, Wang J, Sverdlov M, Chenn A. 2013. AKT activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical development. Neural Dev. 8:7. http://dx.doi.org/10.1186/1749-8104-8-7.
27. Kitagishi Y, Kobayashi M, Kikuta K, Matsuda S. 2012. Roles of PI3K/AKT/GSK3/mTOR pathway in cell signaling of mental illnesses. Depress. Res. Treat. 2012:752563. http://dx.doi.org/10.1155/2012/752563.
28. Higuchi M, Kihara R, Okazaki T, Aoki I, Suetsugu S, Gotoh Y. 2013. Akt1 promotes focal adhesion disassembly and cell motility through phosphorylation of FAK in growth factor-stimulated cells. J. Cell Sci. 126:745-755. http://dx.doi.org/10.1242/jcs.112722.
29. Wiza C, Nascimento EB, Ouwens DM. 2012. Role of PRAS40 in Akt and mTOR signaling in health and disease. Am. J. Physiol. Endocrinol. Metab. 302:E1453-E1460. http://dx.doi.org/10.1152/ajpendo.00660.2011.
30. Hayashi N, Peacock JW, Beraldi E, Zoubeidi A, Gleave ME, Ong CJ. 2012. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ. 19:990-1002. http://dx.doi.org/10.1038/cdd.2011.184.
31. Ning J, Xi G, Clemmons DR. 2011. Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology 152:3143-3154. http://dx.doi.org/10. 1210/en.2011-0155.
32. Yu S, Wong SL, Lau CW, Huang Y, Yu CM. 2011. Oxidized LDL at low concentration promotes in-vitro angiogenesis and activates nitric oxide synthase through PI3K/Akt/eNOS pathway in human coronary artery endothelial cells. Biochem. Biophys. Res. Commun. 407:44-48. http://dx.doi.org/10.1016/j.bbrc.2011. 02.096.
33. Jiang ZY, Zhou QL, Holik J, Patel S, Leszyk J, Coleman K, Chouinard M, Czech MP. 2005. Identification of WNK1 as a substrate of Akt/protein kinase B and a negative regulator of insulin-stimulated mitogenesis in 3T3-L1 cells. J. Biol. Chem. 280:21622-21628. http://dx.doi.org/10.1074/jbc.M414464200. (Pubitemid 40805731)
34. Cheshenko N, Trepanier JB, Stefanidou M, Buckley N, Gonzalez P, Jacobs W, Herold BC. 2013. HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. FASEB J. 27:2584-2599. http://dx.doi.org/10.1096/fj.12-220285.
35. Cotter CR, Jin H, Chen Z. 2014. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog. 10:e1003831. http://dx.doi.org/10.1371/journal.ppat. 1003831.
36. Lozach PY, Huotari J, Helenius A. 2011. Late-penetrating viruses. Curr. Opin. Virol. 1:35-43. http://dx.doi.org/10.1016/j.coviro.2011.05.004.
37. Diering GH, Numata Y, Fan S, Church J, Numata M. 2013. Endosomal acidification by Na+/H+ exchanger NHE5 regulates TrkA cell-surface targeting and NGF-induced PI3K signaling. Mol. Biol. Cell 24:3435-3448. http://dx.doi.org/10. 1091/mbc.E12-06-0445.
38. Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD. 2014. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156:771-785. http://dx.doi.org/10.1016/j.cell.2013.11.049.